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Abstract
h-defensin 2 is produced by a variety of epithelial cell types in the body and exhibits potent antimicrobial activity against a variety of
pathogens, including the bacteria that are most commonly associated with otitis media (OM). The human h-defensin 2 (hBD-2) gene is an
NF-nB regulated gene and a variety of proinflammatory stimuli can induce its expression. Although the presence of molecules of innate
immunity such as lysozyme and lactoferrin has been demonstrated in the middle ear, to date there have been no reports on the expression of
h-defensin 2. In the present study, we demonstrate that h-defensin 2 is expressed in the middle ear mucosa of humans and rats. We also show
that it is expressed in a human middle ear epithelial cell line and that its expression is induced by proinflammatory stimuli such as interleukin
1 alpha (IL-1a), tumor necrosis factor alpha (TNF-a), and lipopolysaccharide (LPS). Moreover, we demonstrate that the transcriptional
activation of hBD-2 gene by IL-1a is mediated through an Src-dependent Raf–MEK1/2–ERK signaling pathway. D 2002 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Otitis media (OM) is the most frequent bacterial infec-
tious disease and the most common cause of hearing
impairment in children. While much progress has been
made towards elucidating the pathogenesis of OM, many
questions remain to be answered. The middle ear cavity of
normal humans and laboratory animals is sterile [1] (unpub-
lished data) and relatively small numbers of immunocytes
are found in the normal tubal and middle ear mucosa [2–4].
Furthermore, although the clearance of bacteria from the
middle ear has been shown to be associated with the
presence of specific antibodies in the effusion and serum
[5–7], there is evidence that other factors may also be
playing a role. In fact, Prellner et al. [8] showed that only 1/
3 of 2-year-old children with recurrent acute OM (rAOM)
had significantly lower levels of antibodies against the
pneumococcal capsular type 19F. The antibody titers in
the rest of the children in the rAOM group were similar to
that found in the age-matched controls. Together, these
findings suggest that under normal conditions, the tubotym-
panum is protected by a highly effective antimicrobial
defense system.
It is now believed that in addition to the components of
the adaptive immune system, the homeostasis of the naso-
pharyngeal tract, eustachian tube, and the middle ear is also
maintained by antimicrobial proteins and peptides that
function to defend these tissues against microbial invasion.
The larger antimicrobial proteins are often lytic enzymes,
nutrient-binding proteins, or proteins containing sites that
target specific microbial macromolecules. The smaller anti-
microbial peptides (defined as peptides containing fewer
than 100 amino acids) act, at least in part, by disrupting the
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structure or function of microbial cell membranes. Included
in the molecules of the innate immune system are the
defensins, lysozyme, lactoferrin, and members of the col-
lectin family including the surfactant proteins [9–13]. In
studies of samples of chronic middle ear effusion, it has
been shown that concentrations of lysozyme, lactoferrin,
and chemotactic molecules were significantly higher in
culture-positive than in sterile effusions, thus suggesting
that the levels of these molecules are increased during
inflammation [14].
The defensins are cationic (polar) molecules with spa-
tially separated hydrophobic and charged regions. In vitro,
the defensins (at micromolar concentrations) have a broad
spectrum of antimicrobial activity against bacteria, fungi,
and even some enveloped viruses [15,16]. In humans and
other vertebrates, the defensins can be divided into the a-
and h-defensin subfamilies on the basis of the position and
bonding of six, conserved cysteine residues. The a-defen-
sins are produced by neutrophils and intestinal Paneth’s
cells [12,17]. The h-defensins, on the other hand, are mainly
produced by epithelial cells of the skin, kidneys, and
trachea-bronchial lining of nearly all vertebrates [18–20].
The h-defensins are released upon microbial invasion and
are located at the host-environment interfaces, such as
mucosal surfaces and skin. Multiple h-defensin genes have
been identified and three have been characterized at the
peptide level [21,60]. Human h-defensin 3 (HBD-3) was
identified by a sequence survey of the genomic region
containing the h-defensin 2 gene and was also isolated
from inflamed human skin [22,61]. HBD-3 mRNA was
found to be expressed in the heart, skeletal muscle, placenta,
skin, esophagus, gingival keratinocytes, trachea, and also in
fetal thymus. Human h-defensin 4 (HBD-4) was recently
characterized based on screening of genomic sequences
[21]. It is expressed in testis, stomach, uterus, neutrophils,
thyroid, lung, and kidney and is inducible by inflammatory
stimuli. Human h-defensin 2 (hBD-2) is produced by
epithelial cells, and exhibits potent antimicrobial activity
against Gram-negative bacteria and Candida. However, it is
not as effective against Gram-positive Staphylococcus aur-
eus [23–25]. hBD-2 represents the first human defensin that
is produced following stimulation of epithelial cells by
contact with microorganisms or cytokines such as TNF-a
and IL-1a. hBD-2 functions as an NF-nB target gene in the
intestinal epithelium and blocking NF-nB activation inhibits
the upregulated expression of hBD-2 in response to IL-1a
stimulation or bacterial infection [24]. The hBD-2 gene and
protein are locally expressed in keratinocytes associated
with inflammatory skin lesions such as psoriasis as well
as in the infected lung epithelia of patients with cystic
fibrosis [24,26]. HBD-1, however, is not affected by IL-
1a and other proinflammatory stimuli, thus suggesting that
unlike the inducible hBD-2 protein, hBD-1 may serve as a
defense in the absence of inflammation. [27,26]. The
presence of hBD-1 has been reported in the in the pars
tensa and pars flaccida of the tympanic membrane and in the
meatal skin [28]. We have recently shown that both hBD-1
and hBD-2 have bactericidal/bacteriostatic activity against
nontypeable Haemophilus influenzae (NTHi), one of the
main OM pathogens [29].
The aim of the present study was to study the expression
and transcriptional regulation of the h-defensin 2 gene and
to elucidate the signaling pathways through which IL-1a
activates the transcription of this gene in human middle ear
epithelial cells. IL-1a has been shown to be upregulated in a
rat model of OM and is a potent activator of h-defensin 2
intestinal epithelial cells [38,27]. Our results suggest that the
IL-1a can upregulate the h-defensin 2 gene in middle ear
epithelial cells and that the transcriptional activation of the
h-defensin 2 gene occurs via an Src-dependent Raf–MEK1/
2–ERK signaling pathway.
2. Materials and methods
2.1. Reagents
Salmonella typhi lipopolysaccharide (LPS), human
recombinant interleukin 1 alpha (IL-1a), tumor necrosis
factor alpha (TNF-a), and tyrphostin AG126 were pur-
chased from Sigma (St. Louis, MO). PP2 and PD98059
were purchased from Calbiochem (La Jolla, CA).
2.2. Immunohistochemistry
Celloidin embedded 20-Am-thick sections of normal and
inflamed mucosa, from archival temporal bone specimens,
were obtained from the House Ear Institute’s Temporal
Bone Collection. Following decelloidination with ether
and absolute ethanol, nonspecific binding sites on the slides
were blocked using normal goat serum. The sections were
then subjected to antigen retrieval (Vector Laboratories,
Burlingame, CA) and incubated with rabbit polyclonal
antibodies against hBD-2 2–1:500 dilution [27]. Signals
were detected by the avidin/biotin complex (ABC) method
(Vector Laboratories).
2.3. Animal studies
Wistar–Kyoto rats free of preexisting middle ear infec-
tion were anesthetized with ketamine/xylazine anesthesia
(300 Al i.p. of sterile saline containing 70 mg/ml ketamine
and 7.5 mg/ml xylazine). Using a 1-ml syringe with a 26-
gauge needle and under a surgical microscope, 50 Al of LPS
(10 Ag/ml) (Sigma), or 50 Al IL-1a (10 ng/ml) (Sigma) was
injected into the middle ear cavity of the animals through
the tympanic membrane. PBS was injected as a control. The
rats were sacrificed after either 8 h (IL-1a) or 48 h (LPS),
and the middle ear mucosa, effusion (LPS), and the eusta-
chian tube tissue were harvested. The 48-h time point was
used for LPS, as this length of time was required for the
accumulation of sufficient quantities of fluid in the middle
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ear cavity for harvesting. Moreover, the LPS effect was not
as rapid as that seen with IL-1a and necessitated a longer
exposure time.
2.4. Cell culture
A549 and HeLa cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
5% fetal bovine serum (Life Technologies, Inc., Gaithers-
burg, MD). The human middle ear epithelial cell line
(HMEEC-1) used in these studies was immortalized with
the E6/E7 genes of human papilloma virus type 16 [30]. The
cells were maintained in a 1:1 mixture of DMEM (Life
Technologies) and bronchial epithelial basal medium
(BEGM) (Clonetics, Walkersville, MD) supplemented with
bovine pituitary extract (52 Ag/ml), hydrocortisone (0.5 Ag/
ml), hEGF (0.5 ng/ml), epinephrine 0.5 (Ag/ml), transferrin
(10 Ag/ml), insulin (5 Ag/ml), triiodothyronine 6.5 ng/ml,
retinoic acid 0.1 ng/ml, gentamycin (50 Ag/ml), and ampho-
tericin-B (50 ng/ml). For studies of the effect of various
inflammatory mediators, the cells were treated with IL-1a
(10 ng/ml), TNF-a (40 ng/ml), IL-6 (100 ng/ml), or LPS (10
Ag/ml) following 40 h of starvation. The concentrations
used are nontoxic to HMEEC-1 cells and have been used in
similar studies with Caco-2 cells [27]. Moreover, there was
no reduction in the expression of housekeeping genes, thus
suggesting the absence of any toxic effects.
For studies of the inhibitory effect of PD98059 and
tyrphostin AG126, the cells were grown to 80% confluence
in six-well culture plates. The medium was then changed to
a 1:1 mixture of DMEM (Life Technologies) and BEGM
(Clonetics) without any additions. After 40 h of starvation,
the cells were then pretreated for 2 h with 50 AM PD98059,
75 AM PD98059, 150 AM AG126, or 200 AM AG126. IL-
1a was then added to the cells to a final concentration of 10
ng/ml and allowed to incubate for10 h. After IL-1a treat-
ment, total RNA was extracted, cDNA was synthesized and
target genes were amplified.
2.5. RT-PCR
Total RNA was extracted from normal and inflamed
middle ear mucosa harvested from patients undergoing
otologic surgery, from normal and from IL-a or LPS treated
rats and from HMEEC-1 cells. The RNA was extracted
using the RNeasyk kit (Qiagen, Valencia, CA) and cDNA
was synthesized with SuperScript II RNase H-reverse tran-
scriptase according to the manufacturer’s protocol (Life
Technologies). The hBD-2 2 gene (accession number
AF071216) was amplified using the following exon-spe-
cific primers: 5V-ATT CCT GAT GCC TCT TCC AG-
3V(forward), 5V-TTG TTC CAG GGA GAC CAC A-
3V(reverse). Use of these primers allows us to distinguish
between amplification of the gene (1.7 kb PCR product)
and the reverse-transcribed mRNA (137 bp PCR product).
The rat h-defensin 2 (accession number AF068861) primers
used for amplification were as follows: 5V-TCT CAT TTC
TCC TGG TGC TG-3V(forward), 5V-TCT AGG CAG TCC
ACA AGT GC-3V(reverse) (143 bp PCR product). The
human 18S ribosomal RNA (accession number M10098)
primers used for amplification were as follows: 5V-GTG
GAG CGA TTT GTC TGG TT-3V(forward), 5V-CGC TGA
GCC AGT CAG TGT AG-3V(reverse) (200 bp PCR
product).
The cDNA was mixed with 20 pmol of each primer and
25 Al of HotStartTaq Master mix (Qiagen) to a final volume
of 50 Al and overlaid with mineral oil (Sigma). The PCR
mixture was first heated to 95 jC for 15 min and then
exposed to 35 cycles (38 cycles for rat hBD-2; 30 cycles for
18S rRNA and human hBD-2 amplified from HMEEC-1
cells) of: 95 jC for 1 min, 50 jC (56 jC for rat hBD-2 and
60 jC for 18S rRNA) for 1 min, and 72 jC for 2 min,
followed by a final elongation step for 3 min at 72 jC in a
model PTC-100 programmable thermal controller (MJ
Research, Inc., Watertown, MA). PCR products were ana-
lyzed by electrophoresis on 1.2% TAE agarose gels, stained
with ethidium bromide, and viewed with UV light. The
identity of the human amplification product was confirmed
by digestion with NdeI (New England Biolabs, Beverly,
MA). The rat product was sequenced directly using the ABI
Prism BigDye Cycle Sequencing kit per the manufacturer’s
instructions (PE, Applied Biosystems, Foster City, CA) on
an ABI Prism 310 Genetic Analyzer (PE, Applied Biosys-
tems).
2.6. Cloning and sequencing of the 5Vflanking region of
hBD-2 gene
The 5Vflanking region (2627 bp from  2625 to + 1) of
the hBD-2 gene (accession number AF071216) [31] was
isolated by PCR amplification with the following primers:
5V-GAG GTA CCT CCA TCC TTT ACT GTG ATG ATG
CC-3V(forward primer with Kpn1 tail), 5V-GAA AGC TTT
GGC TGA TGG CTG GGA GCT TCA CCA (reverse
primer with HindIII tail). The amplified product was subcl-
oned into the multiple cloning site of the pGL3 luciferase
reporter plasmid (Promega, Madison, WI). The resultant
plasmid was named p2.7hBD2-luc and the identity of the
subcloned fragment in p2.7hBD2-luc was confirmed by
DNA sequencing.
2.7. Transfection and luciferase assay
Cells were seeded into six-well plates at a density of
1.5 105 cell/well and transfected when approximately
60% confluent. Transfection was performed using the Trans
ITR-LT 1 Transfection Reagent (PanVera, Madison, WI)
according to the manufacturer’s instructions. For studies of
PD98059 and SB203580 (Calbiochem), 40 h after trans-
fection of p2.7hBD2-luc, HMEEC-1 cells were pretreated
with various concentrations of each compound (PD98059—
10, 25, 50, and 75 AM) (SB203580—1, 5, 10, and 20 AM) for
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2 h, and then exposed to IL-1a (10 ng/ml) for 10 h before
harvesting. For studies of PP2 (Calbiochem), HMEEC-1 cells
were pretreated with various concentrations of the compound
(1, 5, 10, and 20 AM) for 30 min and then exposed to IL-1a
(10 ng/ml) for 10 h before harvesting. For studies of the effect
of the dominant-negative mutants, HMEEC-1 cells were
cotransfected with the p2.7hBD2-luc plasmid (0.7 Ag) and
one containing either the wild-typeMEK cDNA (MEK1WT)
(pCMV5-HMEK1WT) (generous gift of Dr. Alan Saltiel—
University of Michigan), wild-type Raf-1 (Raf WT)
(pCDNA3-RAFWT) (0.5 Ag) (generous gift of Dr. Howard
Goldberg—University of Toronto), the dominant-negative
mutant MEK cDNA (MEK DN) (pCMV5-HMEK1) (0.5 Ag)
(generous gift of Dr. Alan Saltiel—University of Michigan),
or the dominant-negative Raf (Raf DN) (pCDNA3-Raf1)
(generous gift of Dr. Howard Goldberg). A vector (0.5 Ag)
containing no insert was used as a control. Transfected cells
then were starved for 40 h in a 1:1 mixture of DMEM and
BEGM, containing no supplements, followed by exposure to
IL-1a (10 ng/ml) for 10 h before harvesting. All transfections
were carried out in triplicate. The cells were then washed with
phosphate-buffered saline, dissolved in 250 Al of cell culture
lysis reagent (Promega), and harvested by scraping. Lucifer-
ase activity was measured using luminometer (Pharmingen,
La Jolla, CA) after adding luciferase substrate (Promega).
2.8. Western blot analysis
HMEEC-1 cells were grown to 80% confluence in 60
mm culture petri dishes. The medium was then changed to
Fig. 1. Immunohistochemical and RT-PCR analysis of hBD-2 expression in normal human middle ear mocosa and mucosa of from OM patients. (a) The
expression of hBD-2 protein is elevated in diseased human middle ear mucosa. Archival human temporal bone sections were stained with either a polyclonal
anti-hBD-2 antibody (top two panels), or with preimmune serum as negative control (lower two panels) (magnification,  100). (b) The expression of hBD-2
mRNA is higher in mucosa of from OM patients in comparison to that from normal subjects. RT-PCR analysis using fresh human mucosa. The hBD-2 gene
amplification product is 137 bp in length. SM= size marker; N = normal mucosa; D = inflamed mucosa; NC= no cDNA (negative control); hBD= human h-
defensin 2; hBA= human h actin.
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a 1:1 mixture of DMEM (Life Technologies) and BEGM
(Clonetics) without the growth factors. After 40 h of
starvation, the cells were treated with 10 ng/ml of IL-1a
for 5, 15, 30, 45, and 60 min. The cells were lysed with
200 Al of cell lysis buffer (Cell Signaling Technology,
Beverly, MA) supplemented with 1 mM phenylmethylsul-
fonyl flouride (PMSF) (Calbiochem). The lysates were then
centrifuged at 14,000 g for 15 min, and the supernatants
were collected. The protein concentration of the super-
natants was measured using the BCA protein assay (Pierce,
Rockford, IL) and samples were stored at  70 jC. For
Western blotting, the amount equivalent to 20 Ag of protein
was loaded onto 10% Tricine-gels (Invitrogen, Carlsbad,
CA). The gels were run using Tris/Tricine/SDS tank buffer,
pH 7.4, supplemented with 1 mM sodium orthovanadate
(Sigma). After electrophoresis, the proteins were transferred
onto PVDF membranes (0.2 Am, Bio-Rad, Hercules, CA).
After three 5-min washes in TBST (Tris-buffered saline
plus 0.05% Tween-20), the membranes were blocked in
blocking buffer (5% nonfat dry milk in TBST) for 1 h at
room temperature. The membranes were then incubated
overnight at 4 jC with either p44/p42 phospho-ERK anti-
body (1:1000 dilution in blocking buffer) (Cell Signaling
Technology) or p44/p42 ERK antibody (1:1000 dilution in
blocking buffer) (Cell Signaling Technology). Following
the incubation with the primary antibody, the membranes
were washed three times for 5 min each with TBST and
incubated for 1 h at room temperature with HRP-conju-
gated secondary antibody in blocking buffer (Anti-rabbit
IgG, #7074, Cell Signaling Technology). The membranes
were then washed three times with TBST and incubated in
SuperSignal substrate (Pierce) for 1 min at room temper-
ature. The membrane were wrapped in plastic wrap and
exposed to X-ray film.
3. Results and discussion
3.1. Expression of HBD-2 is higher in inflamed middle ear
epithelium in comparison to normal middle ear mucosa
In order to assess the differential expression of the hBD-
2 gene and protein in inflamed and normal human middle
ear epithelium, tissues from OM patients and normal
individuals were subjected to RT-PCR and immunohisto-
chemistry. These studies revealed that the expression of
both hBD-2 mRNA and protein was higher in the mucosa
from OM patients in comparison to that obtained from
normal subjects. As shown in Fig. 1a, hBD-2 protein is
expressed only in the inflamed mucosa, where submucosal
edema and epithelial hyperplasia are also observed. Sim-
ilarly, as shown in Fig. 1b, the 137 bp hBD-2 PCR product
is seen only in the inflamed mucosa and not in normal
middle ear epithelium. The results obtained are consistent
with the outcome of studies of hBD-2 expression in the
skin and the respiratory tract [24,32].
3.2. h-defensin 2 gene is upregulated by IL-1a in vivo and
in vitro
Next, we sought to determine the effects of IL-1a on h-
defensin 2 expression in an experimental model of cytokine-
induced middle ear inflammation. For this study, 50 Al of a
10 ng/ml solution of IL-1a was inoculated into the middle
ear cavity of adult Wistar–Kyoto rats. Middle ear and
eustachian tube mucosa were harvested after 8 h. RT-PCR
analysis showed that IL-1a treatment resulted in a marked
increase in the levels of h-defensin 2 mRNA in the middle
ear and eustachian tube mucosa (Fig. 2a). In fact, the mRNA
for rat h-defensin 2 was only detectable in the mucosa from
the IL-1a treated animals. Similar results were obtained
using bacterial LPS, although the magnitude of the induc-
tion was no as great (data not shown). In order to assess if
treatment with proinflammatory cytokines or LPS could also
induce the levels of h-defensin 2 in human middle ear
epithelium, we exposed cultures of immortalized human
middle ear epithelial cells (HMEEC-1) [30] to IL-1a, TNF-
Fig. 2. IL-1a treatment results in an increase in the level of h defensin 2
mRNA both in vivo and in vitro. (a) h-defensin 2 mRNA levels are elevated
after 8 h of being exposed to IL-1a in a rat model of cytokine-induced
middle ear inflammation. SM= size marker; rLg = rat lung; IL-1a( ) = no
IL-1a added; IL-1a(+) = IL-1a added; rME= rat middle ear tissue; rET= rat
eustachian tube tissue.(b) The mRNA for hBD-2 is induced by treatment
with proinflammatory stimuli in a human middle ear cell line (HMEEC-1).
SM= size marker; hLg = human lung; control = no additions; IL-1a (10 ng/
ml); TNF-a (40 ng/ml); IL-6 (100 ng/ml); LPS (10 Ag/ml); NC= no cDNA.
The data shown are representative of three independent experiments.
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a, IL-6, or LPS. As shown in Fig. 2b, treatment with IL-1a,
TNF-a and LPS resulted in a marked increase in the levels
of hBD-2 mRNA, but the effect of IL-6 was less pro-
nounced. The results obtained with the HMEEC-1 cells
are consistent with data on hBD-2 induction published using
other cell types including airway epithelial cells, and skin,
colon, and gingival epithelial cells [27,33–37]. The degree
of induction resulting from exposure to each of the effector
molecules is, however, different in each system. For exam-
ple, while LPS and TNF-a are potent inducers of hBD-2 in
the airway or gingival epithelial cells, these cytokines have
no effect on hBD-2 expression in the colon epithelial cell
line. We chose IL-1a for our studies of hBD-2 transcrip-
tional regulation because it was the most potent inducer of
hBD-2 mRNA in the HMEEC-1 cells and that its mRNA
level had been shown to be increased during the early phase
of acute OM [38].
3.3. IL-1a activates HBD-2 transcription in human middle
ear epithelial cells
In order to determine if the observed effect of IL-1a on
the levels of hBD-2 mRNA in HMEEC-1 cells was due to
transcriptional activation, we transfected an hBD-2 pro-
moter luciferase reporter construct into HMEEC-1 cells.
The cells were exposed to different concentrations of IL-
1a for 10 h, after which the luciferase activity was
measured. As shown in Fig. 3a, there was a dose-depend-
ent increase in transcriptional activity of the hBD-2
promoter, with a concentration of10 ng/ml of IL-1a giving
the highest luciferase activity. Higher concentrations of IL-
1a, however, had a lower effect, suggesting the activation
of inhibitory mechanisms with exposure to high doses of
this cytokine. Results of a time course of IL-1a treatment
are shown in Fig. 3b and demonstrate that luciferase
activity was indeed at its peak after 10 h of exposure to
the cytokine. By 12 h, however, the activity had started to
decline from its maximal levels. Similar results were also
obtained in other human epithelial cell lines including
A549 and HeLa (data not shown).
3.4. The activation of MEK1/2 is required for the
IL-1a-induced upregulation of HBD-2 gene transcription
The mitogen-activated protein kinase (MAP kinase)
pathways are thought to play the major role in transmitting
extracellular signals to the nucleus and are involved in the
activation of gene transcription by cytokines and other
inflammatory molecules. The extracellular signal-regulated
kinase 1 and 2 (ERK1/2, also called p44/42 MAPK) path-
way is the most extensively studied MAPK pathway
because of its importance in cell proliferation and tumori-
genesis. The p38 MAP kinase, along with its upstream MAP
kinase kinases (MKKs), comprise another important MAP
kinase pathway and are involved in cellular stress responses.
In order to determine the role of the ERK1/2 and p38 MAP
kinase pathways in the activation of hBD-2 transcription by
IL-1a, we made use of inhibitors of each pathway. Pretreat-
ment of cells with PD98059, an inhibitor of MEK1/2,
inhibited the IL-1a-induced upregulation of hBD-2 tran-
scription in a dose-dependent manner (Fig. 4a). Over 70%
of IL-1a effect was inhibited by adding PD98059 to the
cells at a final concentration of 50 AM. The results obtained
with the luciferase assay were also confirmed by PCR
analysis of the levels of hBD-2 mRNA in the cells (Fig.
4b). In addition, we tested the effect of the protein tyrosine
kinase inhibitor, tyrphostin AG126, which blocks the phos-
phorylation of p42/p44 MAPK, on hBD-2 mRNA (Fig. 4b).
As expected, treatment with PD98059, as well as with
Fig. 3. Treatment of HMEEC-1 with IL-1a results in an increase in the
transcriptional activity of the hBD-2 promoter in a dose- and time-
dependent manner. (a) IL-1a upregulates the transcriptional activity of
hBD-2 in a dose-dependent manner (0.1 ng/ml IL-1a P= 0.160; 1.0 ng/ml
IL-1a P= 0.011; 10 ng/ml IL-1a P= 0.013; 25 ng/ml IL-1a P= 0.025; 50
ng/ml IL-1a P= 0.003). (b) Time course of IL-1a effect. The effect of IL-
1a peaked at approximately 10 h posttreatment and declined thereafter.
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AG126, resulted in a dramatic inhibition of the induction of
hBD-2 mRNA in IL-1a-treated HMEEC-1 cells. Treatment
with SB203580, a chemical inhibitor of p38 MAP kinase,
however, had no inhibitory effect at 1, 5, 10, and 20 AM
(data not shown). To confirm the involvement of MEK1/2 in
the IL-1a-induced activation of hBD-2 transcription, a
dominant-negative mutant (MEK1 DN), or a wild-type
(MEK1 WT) form of MEK1/2 was cotransfected with
p2.7hBD2luc into HMEEC-1 cells. Consistent with the
results obtained with PD98059 and AG126, overexpression
of MEK1 DN inhibited the IL-1a-induced hBD-2 promoter
activity by 90%, whereas cotransfection with MEK1 WT
enhanced transcriptional activity by four-fold in comparison
with the vector alone (Fig. 4b). To further confirm our
results regarding the role of the ERK 1/2 pathway, we
performed Western blot analysis of phosphorylated ERK
1/2. ERK phosphorylation reached its peak at 15 min
posttreatment and dropped below control levels by 45 min
Fig. 4. IL-1a activates the transcription of the hBD-2 gene through the MEK1/2 pathway and phosphorlylation of ERK. (a) The MEK1/2 inhibitor, PD98059,
inhibits the IL-1a-induced upregulation of hBD-2 gene transcription in a dose dependent manner. Control = no additions; PD=PD98059. The P values for the
difference between treatment with 10 ng/ml IL-1a alone and adding PD98059 are as follows: 10 ng/ml IL-1a + 10 AM PD98059 P= 0.003; 10 ng/ml IL-
1a + 25 AM PD98059 P= 0.027; 10 ng/ml IL-1a+ 50 AM PD98059 P= 0.015; 10 ng/ml IL-1a + 75 AM PD98059 P= 0.005. (b) Overexpression of the
dominant-negative mutant of MEK 1 (MEK DN) results in a dramatic inhibition of the IL-1a effect. In contrast, overexpression of wild type MEK1 (MEKWT)
enhances the IL-1a effect. Control = no additions; Vect Con = pCMV with no insert; MEK DN= pCMV containing a dominant-negative mutant of MEK; MEK
WT=pCMV containing wild-type MEK. The P values for the difference between vector-transfected cells treated with 10 ng/ml IL-1a and cells transfected
with MEK DN and MEK WT (and also treated with 10 ng/ml IL-1a) are as follows: 10 ng/ml IL-1a +MEK DN P= 0.014; 10 ng/ml IL-1a +MEK WT
P= 0.005. (c) The MEK1/2 inhibitor, PD98059, and the protein tyrosine kinase inhibitor tyrphostin AG126 inhibit the IL-1a-induced upregulation of hBD-2
mRNA levels. The hBD-2 and 18S rRNA amplifications product are 137 and 200 bp in length, respectively. Lane 1 = size marker; lane 2 =media; lane 3 = IL-
1a 10 ng/ml; lane 4 = IL-1a 10 ng/ml + PD98059 (50 AM); lane 5 = IL-1a 10 ng/ml + PD98059 (75 AM); lane 6 = IL-1a 10 ng/ml + tyrphostin AG126 (150
AM); lane 7 = IL-1a 10 ng/ml + tyrphostin AG126 (200 AM). (d) IL-1a treatment results in an increase activation of ERK. Cells treated with 10 ng/ml IL-1a
were analyzed by direct Western blotting of lysates with anti-phospho-ERK (panel a) and anti-pan-ERK antibodies (panel b). The cells were treated with IL-1a
for 5, 15, 30, 45, and 60 min.
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(Fig. 4d). These results suggest that the induction of hBD-2
transcription by IL-1a is mediated through the MEK1/2-
ERK1/2 signaling pathway.
3.5. The Src-dependent Raf pathway, upstream of MEK1/2,
is involved in IL-1a-induced HBD-2 gene upregulation
We then set out to identify the molecules upstream of
MEK1/2 that are involved in the transmission of the tran-
scriptional activation signal for hBD-2. The ERK1/2 path-
way consists of a protein kinase cascade that links growth
and extracellular stress-related signals with transcription in
the nucleus. Binding of ligands to receptor tyrosine kinases
activates the Src protein kinase, which in turn activates
Ras, c-Raf, MEK, and ERK1/2 MAPK. As shown in
Fig. 5a, overexpression of a dominant-negative Raf-1
mutant (Raf DN) resulted in a dose-dependent inhibition
of the IL-1a-induced upregulation of hBD-2 transcription.
Next, we investigated the possible involvement of Src
kinase in the activation of hBD-2 transcription by IL-1a.
The Src-dependent MEK1/2 pathway has been shown to be
required for Pseudomonas aeruginosa-induced overproduc-
tion of mucin in epithelial cells [39] and Src is known to
mediate the bacterially triggered signaling in macrophages
[40]. Pretreatment of HMEEC-1 with a Src-specific chem-
ical inhibitor, PP2, inhibited the IL-1a-induced activation
of hBD-2 transcription in a dose-dependent manner (Fig.
5b). These results strongly suggest that upstream of MEK1/
2, the Src-dependent Raf pathway is involved in the trans-
mission of the IL-1a signal.
IL-1 receptor is a member of Toll family proteins
containing a region of homology known as the Toll/IL-1
receptor (TIR) domain. Upon binding of IL-1 to its recep-
tor, IL-1R associates with the IL-1 receptor accessory
protein (IL-1RAcP) [41,42]. The complex then recruits
and activates an adapter protein-myeloid differentiation
protein (MyD88) [43,44]. MyD88 in turn recruits two
serine–threonine kinases, namely IL-1 receptor-activated
kinase (IRAK) and IRAK2, into the receptor complex [45].
IRAK and IRAK2 interact subsequently with the adapter
molecule, TNF receptor-associated factor 6 (TRAF6)
[46,47], which, in the IL-1R pathway, links them to the
protein kinase NF-nB-inducing kinase (NIK) [48]. At this
point, however, the steps in TLR signaling become less
clear. The oligomerization of TRAF6 maybe linked to
MEKK-1 through ECSIT (evolutionarily conserved signal-
ing intermediate in Toll pathways) [49,50], or alternatively,
through TAB2 [51], it activates TAK-1, a member of the
MAP 3 kinase family [52], which activates, in turn, the InB
kinases. In the IL-1 R pathway, NIK activates the InB
kinase complex (IKKa and IKKh) that directly phosphor-
ylates InB [53–55]. The phosphorylation of InB initiates
its degradation and the translocation of NF-nB to the
nucleus [56].
To date, however, there have been no reports that
directly link the IL-1R to the MEK1/2-ERK pathway. Yet,
there are several lines of evidence suggesting a connection
between IL-1 signaling and the MEK-ERK pathway
[36,57–59]. Our results are consistent with these reports
Fig. 5. The transcriptional activation of the hBD-2 gene is mediated through
Raf-1 and Src. (a) Overexpression of a dominant-negative mutant of Raf-1
(RAF DN) inhibits the IL-1a-induced upregulation of hBD-2 gene
transcription. Control = no additions; Raf DN= pCDNA3 containing a
dominant-negative Raf. The P values for the difference between vector-
transfected cells treated with 10 ng/ml IL-1a and cells transfected with
various amounts of RAF DN (and also treated with 10 ng/ml IL-1a) are as
follows: 10 ng/ml IL-1a + 0.05 Ag RAF DN P= 0.137; 10 ng/ml IL-
1a+ 0.016 Ag RAF DN P= 0.021; 10 ng/ml IL-1a + 1.0 Ag Raf DN
P= 0.01. ( P= 0.093 for the difference between IL-1a-treated cells trans-
fected with 0.05 Ag RAF DN and those transfected with 1.0 Ag RAF DN).
(b) The Src inhibitor, PP2, inhibits the IL-1a effect of hBD-2 transcription
in a dose-dependent manner. Control = no additions. The P values for the
difference between treatment with 10 ng/ml IL-1a alone and adding PP2
are as follows: 10 ng/ml IL-1a+ 1.0 AM PP2 P= 0.20; 10 ng/ml IL-1a + 5.0
AM PP2 P= 0.223; 10 ng/ml IL-1a+ 10 AM PP2 P= 0.015; 10 ng/ml IL-
1a+ 20 AM PP2 P= 0.006.
S.-K. Moon et al. / Biochimica et Biophysica Acta 1590 (2002) 41–5148
and suggest that the activation of IL-1R signaling may lead
to the activation of the Raf-MEK-ERK pathway. A sche-
matic summary of our results is given in Fig. 6. Binding of
IL-1a to its receptor activates hBD-2 transcription through
the activation of Src, Raf, MEK, and ERK as evidenced by
the effect of specific inhibitors and dominant-negative
mutants. How Src contributes to IL-1-induced activation
of MEK-ERK pathway still remains unknown.
In conclusion, our results demonstrate that in comparison
with normal middle ear epithelium, the expression of hBD-
2, both at the mRNA and protein levels, is elevated in
inflamed middle ear mucosa. Moreover, the proinflamma-
tory cytokine, IL-1a, upregulates hBD-2 transcription via
the activation of an Src-dependent Raf-MEK1/2-ERK sig-
naling pathway in human middle ear epithelial cells. Eluci-
dation of the signaling pathway may lead to the
development of novel therapeutic strategies for treatment
of OM.
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